{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:36:43Z","timestamp":1793900203308,"version":"4.8.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"32","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031138","name":"ATMOSPHERE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031138","id-type":"DOI","asserted-by":"publisher"}]},{"name":"PARADIGM-HF"},{"name":"PARAGON-HF"},{"DOI":"10.13039\/501100011746","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011746","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EMPHASIS-HF"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TOPCAT"},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>It remains unclear what the safe serum potassium range is in heart failure (HF) and whether it is the same in HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A patient-level pooled analysis from 12 randomized controlled trials including 32 346 HFrEF and 13 723 HFpEF patients was performed. Baseline serum potassium level was categorized into six groups (&amp;lt;3.5, \u22653.5\u2013&amp;lt;4.0, \u22654.0\u2013&amp;lt;4.5, \u22654.5\u2013&amp;lt;5.0, \u22655.0\u2013&amp;lt;5.5, and \u22655.5 mmol\/L) and serum potassium level at baseline was also analysed as a continuous variable using restricted cubic splines. The primary outcome was all-cause mortality. Secondary outcomes included cardiovascular death, sudden death, pump failure death, first HF hospitalization, and composites of HF hospitalization and cardiovascular or all-cause death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median follow-up was 24.2 and 36.8 months in HFrEF and HFpEF trials, respectively. In HFrEF, serum potassium levels showed a reverse J-shaped association with outcomes. Compared with \u22654.0\u20134.5 mmol\/L (reference), potassium &amp;lt;3.5 mmol\/L was associated with higher risks of all-cause mortality (adjusted hazard ratio 1.49; 95% confidence interval, 1.27\u20131.76), as well as cardiovascular, sudden, and pump failure death. The lowest risk for all outcomes was observed within the baseline serum potassium range of 4.2\u20135.0 mmol\/L, but even \u2018mild hyperkalaemia\u2019 (5.0\u20135.5 mmol\/L) was not associated with worse outcomes in HFrEF. Although the risk curve was U-shaped and flatter in HFpEF, the lowest incidence of all outcomes was observed over the same potassium range as HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In HFrEF, hypokalaemia is strongly associated with worse outcomes and should be avoided. In terms of safety, the optimal serum potassium concentration in both HFrEF and HFpEF appears to be in the range 4.2\u20135.0 mmol\/L.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehag341","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:47:53Z","timestamp":1776430073000},"page":"4480-4499","source":"Crossref","is-referenced-by-count":7,"title":["Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis"],"prefix":"10.1093","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4875-7470","authenticated-orcid":false,"given":"Ryohei","family":"Ono","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Chimura","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]},{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine , Suita ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8903-4906","authenticated-orcid":false,"given":"Alasdair D","family":"Henderson","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Campbell","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3010-5589","authenticated-orcid":false,"given":"Michel","family":"Komajda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Saint Joseph , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1828-2387","authenticated-orcid":false,"given":"Milton","family":"Packer","sequence":"additional","affiliation":[{"name":"Baylor Scott & White Health , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-275X","authenticated-orcid":false,"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine-Cardiology, University of Michigan School of Medicine , Ann Arbor, MI ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R","family":"Teerlink","sequence":"additional","affiliation":[{"name":"Section of Cardiology, SanFrancisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Inserm Clinical Investigation Centre, CHU, Universite\u0301 de Lorraine , Nancy ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6387-1351","authenticated-orcid":false,"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Minnesota , Minneapolis, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Yang","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-9597","authenticated-orcid":false,"given":"Scott D","family":"Solomon","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6317-3975","authenticated-orcid":false,"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow , 126 University Place, Glasgow G12 8TA ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2026082319570730000_ehag341-B1","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026082319570730000_ehag341-B2","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","article-title":"Associations of serum potassium levels with mortality in chronic heart failure patients","volume":"38","author":"Aldahl","year":"2017","journal-title":"Eur Heart J"},{"key":"2026082319570730000_ehag341-B3","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1016\/j.jacc.2020.04.021","article-title":"Abnormalities of potassium in heart failure: JACC state-of-the-art review","volume":"75","author":"Ferreira","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026082319570730000_ehag341-B4","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"Nunez","year":"2018","journal-title":"Circulation"},{"key":"2026082319570730000_ehag341-B5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jacc.2025.01.011","article-title":"Do potassium binders block both the benefits and the risks of mineralocorticoid receptor antagonists in heart failure? The four anti-aldosterone myths","volume":"85","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026082319570730000_ehag341-B6","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/ehf2.14285","article-title":"Serum potassium level and mineralocorticoid receptor antagonist dose in a large cohort of chronic heart failure patients","volume":"10","author":"Clephas","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026082319570730000_ehag341-B7","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1056\/NEJMoa2509542","article-title":"Increasing the potassium level in patients at high risk for ventricular arrhythmias","volume":"393","author":"Jons","year":"2025","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.amjcard.2016.09.038","article-title":"Serum potassium levels and outcome in acute heart failure (data from the PROTECT and COACH trials)","volume":"119","author":"Tromp","year":"2017","journal-title":"Am J Cardiol"},{"key":"2026082319570730000_ehag341-B9","doi-asserted-by":"publisher","first-page":"4352","DOI":"10.1002\/ehf2.14086","article-title":"Dyskalemia in people at increased risk for heart failure: findings from the heart \u2018OMics\u2019 in AGEing (HOMAGE) trial","volume":"9","author":"Monzo","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026082319570730000_ehag341-B10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","article-title":"Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction","volume":"7","author":"Savarese","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026082319570730000_ehag341-B11","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"2026082319570730000_ehag341-B12","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ejhf.2134","article-title":"Serum potassium and outcomes in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial","volume":"23","author":"Ferreira","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026082319570730000_ehag341-B13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"2026082319570730000_ehag341-B14","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B15","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa1514859","article-title":"Aliskiren, enalapril, or aliskiren and enalapril in heart failure","volume":"374","author":"McMurray","year":"2016","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1056\/NEJMoa1514859","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2026082319570730000_ehag341-B17","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B18","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B19","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B20","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B21","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B22","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1056\/NEJMoa2025797","article-title":"Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure","volume":"384","author":"Teerlink","year":"2021","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"2026082319570730000_ehag341-B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2026082319570730000_ehag341-B25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.cardfail.2005.06.432","article-title":"The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design","volume":"11","author":"Carson","year":"2005","journal-title":"J Card Fail"},{"key":"2026082319570730000_ehag341-B26","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"2026082319570730000_ehag341-B27","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026082319570730000_ehag341-B28","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","article-title":"Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in Heart Failure trial (PARADIGM-HF)","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"2026082319570730000_ehag341-B29","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432","article-title":"A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026082319570730000_ehag341-B30","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/ejhf.1548","article-title":"The dapagliflozin and prevention of adverse-outcomes in heart failure (DAPA-HF) trial: baseline characteristics","volume":"21","author":"McMurray","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026082319570730000_ehag341-B31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1161\/CIRCHEARTFAILURE.112.972794","article-title":"Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"6","author":"Shah","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026082319570730000_ehag341-B32","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ejhf.3266","article-title":"Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"26","author":"Solomon","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026082319570730000_ehag341-B33","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026082319570730000_ehag341-B34","doi-asserted-by":"publisher","first-page":"e004962","DOI":"10.1161\/CIRCHEARTFAILURE.118.004962","article-title":"Baseline characteristics of patients with heart failure and preserved ejection fraction in the PARAGON-HF trial","volume":"11","author":"Solomon","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026082319570730000_ehag341-B35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/s1071-9164(99)90013-1","article-title":"Candesartan in heart failure\u2013assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators","volume":"5","author":"Swedberg","year":"1999","journal-title":"J Card Fail"},{"key":"2026082319570730000_ehag341-B36","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1002\/ejhf.2015","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials","volume":"22","author":"Teerlink","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026082319570730000_ehag341-B37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF","volume":"8","author":"Teerlink","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026082319570730000_ehag341-B38","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/ejhf.3253","article-title":"Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: rationale and design of the FINEARTS-HF trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026082319570730000_ehag341-B39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2026082319570730000_ehag341-B40","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/ejhf.1371","article-title":"Clinical and research implications of serum versus plasma potassium measurements","volume":"21","author":"Cooper","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026082319570730000_ehag341-B41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1037\/a0016973","article-title":"An introduction to recursive partitioning: rationale, application, and characteristics of classification and regression trees, bagging, and random forests","volume":"14","author":"Strobl","year":"2009","journal-title":"Psychol Methods"},{"key":"2026082319570730000_ehag341-B42","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1093\/eurheartj\/ehaf623","article-title":"Hypokalaemia and atrial fibrillation detected by implanted loop recorders","volume":"46","author":"Hessellund","year":"2025","journal-title":"Eur Heart J"},{"key":"2026082319570730000_ehag341-B43","doi-asserted-by":"publisher","first-page":"1E","DOI":"10.1016\/0002-9149(90)90243-t","article-title":"Hormone-electrolyte interactions in congestive heart failure: lessons from a 4,000-year-old sumerian tablet","volume":"65","author":"Packer","year":"1990","journal-title":"Am J Cardiol"},{"key":"2026082319570730000_ehag341-B44","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.34067\/KID.0000000903","article-title":"Potassium dysregulation in patients with CKD: time to focus on low potassium intake and hypokalemia","volume":"6","author":"Wilcox","year":"2025","journal-title":"Kidney360"},{"key":"2026082319570730000_ehag341-B45","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.jchf.2024.08.003","article-title":"Patiromer for heart failure medication optimization in patients with current or past hyperkalemia: DIAMOND subanalysis","volume":"12","author":"Coats","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026082319570730000_ehag341-B46","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1002\/ehf2.14661","article-title":"Epidemiology and risk factors for hyperkalaemia in heart failure","volume":"11","author":"Grobbee","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026082319570730000_ehag341-B47","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.009429","article-title":"Hyperkalemia in heart failure: probably not O\u201cK\u201d","volume":"7","author":"Fudim","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026082319570730000_ehag341-B48","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure","volume":"85","author":"Kosiborod","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026082319570730000_ehag341-B49","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.amjcard.2016.08.078","article-title":"Serum potassium levels and outcome in patients with chronic heart failure","volume":"118","author":"Hoss","year":"2016","journal-title":"Am J Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/32\/4480\/68418928\/ehag341.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/47\/32\/4480\/68418928\/ehag341.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T23:57:14Z","timestamp":1787529434000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/47\/32\/4480\/8697275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":49,"journal-issue":{"issue":"32","published-online":{"date-parts":[[2026,5,28]]},"published-print":{"date-parts":[[2026,8,24]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag341","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,21]]},"published":{"date-parts":[[2026,5,28]]}}}